This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Aceragen Performance dei guadagni passati
Il passato criteri di controllo 0/6
Aceragen has been growing earnings at an average annual rate of 28.9%, while the Biotechs industry saw earnings growing at 23.7% annually. Revenues have been growing at an average rate of 34.1% per year.
Informazioni chiave
28.9%
Tasso di crescita degli utili
40.3%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 17.0% |
Tasso di crescita dei ricavi | 34.1% |
Rendimento del capitale proprio | -71.6% |
Margine netto | -559.9% |
Ultimo aggiornamento sui guadagni | 31 Mar 2023 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Ripartizione dei ricavi e delle spese
Come Aceragen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
31 Mar 23 | 7 | -41 | 15 | 0 |
31 Dec 22 | 5 | -23 | 12 | 0 |
30 Sep 22 | 0 | -16 | 9 | 16 |
30 Jun 22 | 0 | -18 | 9 | 10 |
31 Mar 22 | 0 | -20 | 9 | -7 |
31 Dec 21 | 0 | 97 | 10 | 0 |
30 Sep 21 | 0 | 24 | 11 | 5 |
30 Jun 21 | 0 | 9 | 11 | 25 |
31 Mar 21 | 0 | -8 | 11 | 29 |
31 Dec 20 | 0 | -113 | 12 | 25 |
30 Sep 20 | 0 | -87 | 12 | 22 |
30 Jun 20 | 0 | -78 | 13 | 9 |
31 Mar 20 | 1 | -65 | 13 | 9 |
31 Dec 19 | 1 | -85 | 12 | 35 |
30 Sep 19 | 2 | -45 | 13 | 10 |
30 Jun 19 | 2 | -46 | 14 | 5 |
31 Mar 19 | 0 | -51 | 15 | 13 |
31 Dec 18 | 1 | -60 | 15 | 42 |
30 Sep 18 | 1 | -63 | 16 | 19 |
30 Jun 18 | 1 | -66 | 15 | 24 |
31 Mar 18 | 1 | -71 | 15 | 25 |
31 Dec 17 | 1 | -66 | 16 | 26 |
30 Sep 17 | 16 | -50 | 15 | 26 |
30 Jun 17 | 16 | -49 | 15 | 25 |
31 Mar 17 | 16 | -41 | 15 | 25 |
31 Dec 16 | 16 | -38 | 15 | 24 |
30 Sep 16 | 1 | -51 | 15 | 22 |
30 Jun 16 | 1 | -50 | 15 | 21 |
31 Mar 16 | 1 | -49 | 15 | 22 |
31 Dec 15 | 0 | -49 | 15 | 20 |
30 Sep 15 | 0 | -49 | 15 | 19 |
30 Jun 15 | 0 | -47 | 14 | 20 |
31 Mar 15 | 0 | -42 | 13 | 17 |
31 Dec 14 | 0 | -39 | 11 | 16 |
30 Sep 14 | 0 | -34 | 10 | 14 |
30 Jun 14 | 0 | -29 | 9 | 11 |
31 Mar 14 | 0 | -26 | 8 | 9 |
31 Dec 13 | 0 | -21 | 8 | 7 |
30 Sep 13 | 0 | -21 | 7 | 7 |
30 Jun 13 | 0 | -21 | 6 | 8 |
31 Mar 13 | 0 | -19 | 6 | 9 |
31 Dec 12 | 0 | -22 | 6 | 13 |
30 Sep 12 | 0 | -26 | 7 | 12 |
Guadagni di qualità: ACGN is currently unprofitable.
Margine di profitto in crescita: ACGN is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ACGN is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.
Accelerare la crescita: Unable to compare ACGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: ACGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Rendimento del capitale proprio
ROE elevato: ACGN has a negative Return on Equity (-71.58%), as it is currently unprofitable.